CCR5 and ductal breast carcinoma in situ: We next examined CCR5 vasculature in Triple Negative (TNBC), Human Epidermal Growth Factor Receptor 2 (HER2)+ and Estrogen Receptor (ER)+ breast cancers; as well as ductal carcinoma in situ (DCIS) [23].